Brokerages forecast that Spero Therapeutics Inc (NASDAQ:SPRO) will announce sales of $890,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Spero Therapeutics’ earnings. The highest sales estimate is $1.28 million and the lowest is $400,000.00. Spero Therapeutics posted sales of $990,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 10.1%. The company is scheduled to announce its next quarterly earnings results on Monday, April 1st.
According to Zacks, analysts expect that Spero Therapeutics will report full-year sales of $3.20 million for the current financial year, with estimates ranging from $2.67 million to $3.55 million. For the next year, analysts expect that the firm will report sales of $11.80 million, with estimates ranging from $7.50 million to $18.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Thursday, November 8th. The company reported ($0.60) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Spero Therapeutics had a negative net margin of 1,402.91% and a negative return on equity of 52.22%. The firm had revenue of $0.66 million during the quarter, compared to the consensus estimate of $0.66 million.
Several brokerages have commented on SPRO. Cantor Fitzgerald set a $27.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Thursday, September 27th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Sunday, September 30th. Zacks Investment Research downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. Finally, Bank of America downgraded shares of Spero Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $19.00 to $9.00 in a research note on Tuesday, October 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $20.70.
Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in shares of Spero Therapeutics during the third quarter worth $126,000. PNC Financial Services Group Inc. bought a new stake in shares of Spero Therapeutics during the second quarter worth $146,000. Millennium Management LLC bought a new stake in shares of Spero Therapeutics during the first quarter worth $163,000. Highland Capital Management LP bought a new stake in shares of Spero Therapeutics during the third quarter worth $210,000. Finally, Bank of New York Mellon Corp increased its position in shares of Spero Therapeutics by 73.9% during the second quarter. Bank of New York Mellon Corp now owns 24,689 shares of the company’s stock worth $363,000 after acquiring an additional 10,490 shares in the last quarter. 52.93% of the stock is owned by institutional investors.
Shares of NASDAQ:SPRO opened at $6.75 on Friday. Spero Therapeutics has a 52 week low of $6.45 and a 52 week high of $19.00. The company has a market capitalization of $123.37 million and a price-to-earnings ratio of -0.38.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Further Reading: What is the LIBOR?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.